Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection. We resubmitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). The FDA has assigned a PDUFA date of June 19,2020 for CONTEPO. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.
Events & Presentations
Thursday June 4, 2020 1:00 PM EDT
Jefferies Virtual Healthcare Conference
Wednesday May 13, 2020 11:00 AM EDT
BofA Securities 2020 Virtual Health Care Conference
Monday May 11, 2020 4:30 PM EDT
Nabriva Therapeutics First Quarter 2020 Financial Results Call